ID: ALA3355391

Max Phase: Preclinical

Molecular Formula: C16H15F3N6

Molecular Weight: 348.33

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  FC(F)(F)c1ccc(N2CCN(c3ncnc4[nH]cnc34)CC2)cc1

Standard InChI:  InChI=1S/C16H15F3N6/c17-16(18,19)11-1-3-12(4-2-11)24-5-7-25(8-6-24)15-13-14(21-9-20-13)22-10-23-15/h1-4,9-10H,5-8H2,(H,20,21,22,23)

Standard InChI Key:  QWRNNQOCHGOFJK-UHFFFAOYSA-N

Associated Targets(Human)

T47D 39041 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PLC 23 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mahlavu 271 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Huh-7 12904 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 348.33Molecular Weight (Monoisotopic): 348.1310AlogP: 2.70#Rotatable Bonds: 2
Polar Surface Area: 60.94Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.84CX Basic pKa: 3.89CX LogP: 3.02CX LogD: 3.02
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.77Np Likeness Score: -1.48

References

1. Demir Z, Guven EB, Ozbey S, Kazak C, Atalay RC, Tuncbilek M..  (2015)  Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,  89  [PMID:25462277] [10.1016/j.ejmech.2014.10.080]

Source